FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1483779827> ?p ?o ?g. }

• W1483779827 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAMetronomic chemotherapy (MCT) refers to the chronic, equally spaced, delivery of low doses of different chemotherapeutic drugs, without extended interruptions. We have already demonstrated that MCT, as an intervention strategy, of metronomic Cy combined with celecoxib or doxorubicin inhibits mammary tumors growth. Our present aim was to analyze the antitumor and antimetastatic effects of MCT of Cy combined with Met. Inbred CBi mice were s.c. or i.v. challenged with M-406 tumor (Day 0), and treated when the tumors reached a volume of 100 a 150 mm3 (s.c.) or from Day 3 (i.v.) on, with: I) no further treatment (controls); II) Cy in the drinking water (20-30 mg/kg body weight/day); III) Met 3 times/week by gavage (100 mg/kg); IV) Treated as II + III. Tumors were measured and animals weighed twice a week and blood samples for glycemia determination were taken. On day 36 tumor volume in group IV (mm3, mean ± SEM: 929.7 ± 213.8) was lower than in groups I (2880.0 ± 1530.0), II (2896.4 ± 976.9) and III (3772.0 ± 68.0). On day 46, with only two groups remaining, tumor volume in group IV was lower than that in group II (p=0.032). All the groups differed in tumor volume doubling time (days, mean ± SEM; I: 3.8 ± 0.3, II: 5.3 ± 0.7, III: 3.6 ± 0.4, IV: 5.4 ± 0.2) (p<0.05). All the groups differed in survival (days, median, I: 30.5; II: 44; III: 29; IV: 50) (p=0.0063), showing group IV the highest one. There were neither weight losses nor changes in the glycemia with respect to basal values both in s.c. and i.v. experiments. In the i.v. experiment, animals were sacrificed on day 13, when the first mouse showed signs of metastatic illness. The number and diameter of lung metastasis were determined and total metastatic volume (TMV) was calculated. The experimental groups differed in TMV (p<0.0001), being those of groups II (mm3, mean ± SEM: 162.1 ± 41.4) and IV (218.6 ± 31.3) significantly lower (p<0.001 and p<0.01, respectively) than those in groups I (491.3 ± 80.6) and III (432.3 ± 54.5). These results clearly show that metronomic chemotherapy with a combination of cyclophosphamide and metformin significantly inhibits tumor growth and increase survival, also decreasing the development of metastasis of a murine mammary adenocarcinoma, while being devoid of toxicity.Citation Format: Antonela S. Asad, Jesus Basualdo, Lucia Micheletti, Maria C. Capello Gardenal, Herman A. Perroud, Maria J. Rico, Viviana R. Rozados, O. Graciela Scharovsky. Metronomic chemotherapy with cyclophosphamide and metformin inhibits tumor and metastasis growth M-406 murine mammary adenocarcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 795. doi:10.1158/1538-7445.AM2014-795" @default.
• W1483779827 created "2016-06-24" @default.
• W1483779827 creator A5005300802 @default.
• W1483779827 creator A5006016730 @default.
• W1483779827 creator A5015007605 @default.
• W1483779827 creator A5023524397 @default.
• W1483779827 creator A5026376296 @default.
• W1483779827 creator A5028390439 @default.
• W1483779827 creator A5056725736 @default.
• W1483779827 creator A5086707447 @default.
• W1483779827 date "2014-09-30" @default.
• W1483779827 modified "2023-09-27" @default.
• W1483779827 title "Abstract 795: Metronomic chemotherapy with cyclophosphamide and metformin inhibits tumor and metastasis growth M-406 murine mammary adenocarcinoma" @default.
• W1483779827 doi "https://doi.org/10.1158/1538-7445.am2014-795" @default.
• W1483779827 hasPublicationYear "2014" @default.
• W1483779827 type Work @default.
• W1483779827 sameAs 1483779827 @default.
• W1483779827 citedByCount "0" @default.
• W1483779827 crossrefType "proceedings-article" @default.
• W1483779827 hasAuthorship W1483779827A5005300802 @default.
• W1483779827 hasAuthorship W1483779827A5006016730 @default.
• W1483779827 hasAuthorship W1483779827A5015007605 @default.
• W1483779827 hasAuthorship W1483779827A5023524397 @default.
• W1483779827 hasAuthorship W1483779827A5026376296 @default.
• W1483779827 hasAuthorship W1483779827A5028390439 @default.
• W1483779827 hasAuthorship W1483779827A5056725736 @default.
• W1483779827 hasAuthorship W1483779827A5086707447 @default.
• W1483779827 hasConcept C121608353 @default.
• W1483779827 hasConcept C126322002 @default.
• W1483779827 hasConcept C143998085 @default.
• W1483779827 hasConcept C2776187077 @default.
• W1483779827 hasConcept C2776467144 @default.
• W1483779827 hasConcept C2776694085 @default.
• W1483779827 hasConcept C2776755627 @default.
• W1483779827 hasConcept C2779013556 @default.
• W1483779827 hasConcept C2781182431 @default.
• W1483779827 hasConcept C2781303535 @default.
• W1483779827 hasConcept C530470458 @default.
• W1483779827 hasConcept C71924100 @default.
• W1483779827 hasConcept C90924648 @default.
• W1483779827 hasConceptScore W1483779827C121608353 @default.
• W1483779827 hasConceptScore W1483779827C126322002 @default.
• W1483779827 hasConceptScore W1483779827C143998085 @default.
• W1483779827 hasConceptScore W1483779827C2776187077 @default.
• W1483779827 hasConceptScore W1483779827C2776467144 @default.
• W1483779827 hasConceptScore W1483779827C2776694085 @default.
• W1483779827 hasConceptScore W1483779827C2776755627 @default.
• W1483779827 hasConceptScore W1483779827C2779013556 @default.
• W1483779827 hasConceptScore W1483779827C2781182431 @default.
• W1483779827 hasConceptScore W1483779827C2781303535 @default.
• W1483779827 hasConceptScore W1483779827C530470458 @default.
• W1483779827 hasConceptScore W1483779827C71924100 @default.
• W1483779827 hasConceptScore W1483779827C90924648 @default.
• W1483779827 hasLocation W14837798271 @default.
• W1483779827 hasOpenAccess W1483779827 @default.
• W1483779827 hasPrimaryLocation W14837798271 @default.
• W1483779827 hasRelatedWork W1443108546 @default.
• W1483779827 hasRelatedWork W1976144347 @default.
• W1483779827 hasRelatedWork W2328569641 @default.
• W1483779827 hasRelatedWork W2328602479 @default.
• W1483779827 hasRelatedWork W2349623012 @default.
• W1483779827 hasRelatedWork W2367644126 @default.
• W1483779827 hasRelatedWork W2370809356 @default.
• W1483779827 hasRelatedWork W2376976586 @default.
• W1483779827 hasRelatedWork W2380703843 @default.
• W1483779827 hasRelatedWork W2387432767 @default.
• W1483779827 hasRelatedWork W2388342914 @default.
• W1483779827 hasRelatedWork W2388762021 @default.
• W1483779827 hasRelatedWork W2389789178 @default.
• W1483779827 hasRelatedWork W2419609823 @default.
• W1483779827 hasRelatedWork W2533964947 @default.
• W1483779827 hasRelatedWork W2588538618 @default.
• W1483779827 hasRelatedWork W2784043644 @default.
• W1483779827 hasRelatedWork W3030032982 @default.
• W1483779827 hasRelatedWork W3030508989 @default.
• W1483779827 hasRelatedWork W3211138513 @default.
• W1483779827 isParatext "false" @default.
• W1483779827 isRetracted "false" @default.
• W1483779827 magId "1483779827" @default.
• W1483779827 workType "article" @default.